Where Axon Enterprise Stands With Analysts

Analysts have provided the following ratings for Axon Enterprise (NASDAQ:AXON) within the last quarter: Bullish Somewhat Bullish Indifferent…

Analysts have provided the following ratings for Axon Enterprise (NASDAQ:AXON) within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 2 1 0 0
Last 30D 0 0 1 0 0
1M Ago 1 2 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

These 4 analysts have an average price target of $236.0 versus the current price of Axon Enterprise at $198.96, implying upside.

Below is a summary of how these 4 analysts rated Axon Enterprise over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

price target chart

This current average represents a 2.28% decrease from the previous average price target of $241.50.

Stay up to date on Axon Enterprise analyst ratings.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

iDoseTR Approval Sets Stage for Glaukos’ Game-Changing Product, Surpassing Market Expectations, Says Analyst

Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure in patients with ocular hypertension 

GKOS